Related Experiment Video
Updated: Jan 27, 2026

Chromatin Extraction from Frozen Chimeric Liver Tissue for Chromatin Immunoprecipitation Analysis
Published on: March 23, 2021
Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity
Erin R Aho1, Jing Wang2, Rocco D Gogliotti3
1Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Abstract:
The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in cancer. Drug discovery efforts center on the blockade of the "WIN site" of WDR5, a well-defined pocket that is amenable to small molecule inhibition. Various cancer contexts have been proposed to be targets for WIN site inhibitors, but a lack of understanding of WDR5 target genes and of the primary effects of WIN site inhibitors hampers their utility. Here, by the discovery of potent WIN site inhibitors, we demonstrate that the WIN site links WDR5 to chromatin at a small cohort of loci, including a specific subset of ribosome protein genes. WIN site inhibitors rapidly displace WDR5 from chromatin and decrease the expression of associated genes, causing translational inhibition, nucleolar stress, and p53 induction. Our studies define a mode by which WDR5 engages chromatin and forecast that WIN site blockade could have utility against multiple cancer types.
Insights
WIN site inhibitors block the chromatin protein WDR5, impacting cancer-related ribosome genes. This leads to reduced protein production and may offer new cancer treatment strategies.
Area of Science:
- Molecular Biology
- Cancer Biology
- Pharmacology
Background:
- The chromatin-associated protein WDR5 is a key target for cancer drug development.
- Current drug discovery focuses on inhibiting the WDR5 WIN site, but the precise WDR5 target genes and inhibitor effects are not fully understood.
Purpose of the Study:
- To investigate the role of the WDR5 WIN site in chromatin association and gene regulation.
- To elucidate the primary effects of WIN site inhibitors in cancer contexts.
Main Methods:
- Discovery and application of potent small molecule WIN site inhibitors.
- Analysis of WDR5 chromatin binding and gene expression changes.
- Assessment of downstream cellular effects including translation, nucleolar stress, and p53 induction.
Main Results:
- The WDR5 WIN site was found to link WDR5 to a specific set of chromatin loci, including ribosome protein genes.
- WIN site inhibitors rapidly displaced WDR5 from chromatin and decreased target gene expression.
- Inhibitor treatment resulted in translational inhibition, nucleolar stress, and p53 activation.
Conclusions:
- WDR5 engages chromatin via its WIN site, regulating a specific cohort of genes.
- WIN site blockade effectively inhibits WDR5 function, leading to cancer-relevant cellular responses.
- Targeting the WDR5 WIN site shows promise for treating various cancer types.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Electron Affinity
Chromatin Packaging
The chromatin
In combination with specialized DNA binding protein called Histones, the DNA double helix forms a compact DNA: protein complex called chromatin. The chromatin itself is further compacted into higher-order...
Affinity and Avidity
Spreading of Chromatin Modifications
Writers
The writer...
Inheritance of Chromatin Structures

